The estimated Net Worth of Anthony Natale is at least $450 ezer dollars as of 28 November 2022. Anthony Natale owns over 102,859 units of Venus Concept stock worth over $346,350 and over the last 5 years he sold VERO stock worth over $68,914. In addition, he makes $35,000 as Independent Director at Venus Concept.
Anthony has made over 2 trades of the Venus Concept stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 102,859 units of VERO stock worth $25,715 on 28 November 2022.
The largest trade he's ever made was selling 154,284 units of Venus Concept stock on 22 November 2022 worth over $43,200. On average, Anthony trades about 36,735 units every 1 days since 2019. As of 28 November 2022 he still owns at least 641,507 units of Venus Concept stock.
You can see the complete history of Anthony Natale stock trades at the bottom of the page.
Dr. Anthony J. Natale M.D. serves as Independent Director of the Company. Dr. Natale has served as a Managing Partner at Aperture Venture Partners, a healthcare venture capital firm, since 2010. From 2006 to 2010 and 2002 to 2006, respectively, Dr. Natale was a Partner at Prism Ventures and MDS Capital, where he made and managed healthcare venture investments. He has been a founder, director and/or lead investor of numerous venture-backed life sciences companies. Dr. Natale currently serves on the board of directors of Channel Medsystems, Cortica, and Neuros Medical. He previously has had board roles at multiple portfolio companies, including Xlumena, Spirox, Mako Surgical, Inspire Medical, Avedro, Otonomy and Entrigue Surgical. He holds a B.A. from the University of Virginia, an M.D. from the University of Florida and an M.B.A. from Yale University. Prior to transitioning into venture capital, Dr. Natale trained in General Surgery and Otolaryngology/Head and Neck Surgery at the University of Connecticut and Hartford Hospital. Venus Concept believes that Dr. Natale is qualified to serve on Venus Concept’s board of directors based on experience investing in healthcare companies, his experience on board of directors in the healthcare industry, and his medical training.
As the Independent Director of Venus Concept, the total compensation of Anthony Natale at Venus Concept is $35,000. There are 9 executives at Venus Concept getting paid more, with Domenic Serafino having the highest compensation of $763,479.
Anthony Natale is 46, he's been the Independent Director of Venus Concept since 2019. There are 19 older and 5 younger executives at Venus Concept. The oldest executive at Venus Concept Inc. is Kenji Shimizu, 68, who is the Interim Chief Innovation Officer.
Anthony's mailing address filed with the SEC is 235 YORKLAND BLVD., SUITE 900, TORONTO, A6, M2J 4Y8.
Over the last 5 years, insiders at Venus Concept have traded over $1,569,538 worth of Venus Concept stock and bought 13,477,963 units worth $14,979,486 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Gilbert H Kliman és Richard Scott Barry. On average, Venus Concept executives and independent directors trade stock every 46 days with the average trade being worth of $222,494. The most recent stock trade was executed by Michael Willingham Masters ... on 7 June 2024, trading 489,948 units of VERO stock currently worth $587,938.
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
Venus Concept executives and other stock owners filed with the SEC include: